Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 EUR | +2.77% | +1.21% | +3.09% |
Mar. 15 | Naturhouse Health, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Naturhouse Health, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 9.56 for the current year.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- Most analysts recommend that the stock should be sold or reduced.
Ratings chart - Surperformance
Sector: Other Specialty Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.09% | 106M | - | ||
+30.82% | 30.4B | A- | ||
+7.44% | 5.89B | B- | ||
-17.46% | 4.17B | C | ||
+6.85% | 4B | C+ | ||
+4.23% | 1.91B | - | B- | |
-8.36% | 1.69B | C+ | ||
-15.50% | 1.23B | - | C | |
-13.44% | 1.16B | B- | ||
-21.13% | 944M | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NTH Stock
- Ratings Naturhouse Health, S.A.